Changyu Pharmaceutical Co., Ltd.
昌郁医药
Changyu Pharmaceutical Co., Ltd.
Biotech/Healthcare
Changyu Pharmaceutical has completed a RMB 250 million Series D financing round. The funds will be used for clinical research on its core products and pipeline development, accelerating the global commercialization of its innovative drugs.
Latest round: Series D (2026)
Source: ChinaBulls — chinabulls.com
Last updated 2026-07-28
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.